Metabolic Disorder Collaboration Agreement

Collaboration Agreement

You are currently viewing:

This Collaboration Agreement involves

CuraGen Corporation | Bayer Corporation

. RealDealDocs™ contains millions of easily searchable legal documents and clauses from top law firms. Search for free - click here.

Title: Metabolic Disorder Collaboration Agreement
Date: 3/14/2006
Industry: BIOTRX Law Firm: Wilmer Cutler Sector: HEALTH

Search Collaboration Agreement by:

Exhibit 10.30

November 11, 2005

Bayer Pharmaceuticals Corporation

400 Morgan Lane

West Haven, CT 06516-4175

ATTN: Legal Department

Gentlemen:

Reference is made to the Metabolic Disorder Collaboration Agreement dated January 12, 2001 between Bayer Corporation and CuraGen Corporation (as previously amended, the “Agreement”). Terms which are defined in the Agreement are used herein as so defined. This letter will set forth our agreement with respect to an amendment of the Agreement.

Notwithstanding the provisions of Section 4.1(a)(iii) or any other provision of the Agreement, effective October 31, 2005 CuraGen shall not bear any further Development Costs of the Metabolic Program relating to the Pre-Clinical Development Phase, Clinical Development Phase and/or Commercialization Phase with respect to the Development Compound known as CT052 and any Metabolic Program Drug developed from such Development Compound. Pursuant to Section 2.4(e), CuraGen will, following October 31, 2005, no longer have any representatives on the